Want to see HK:1099 full AI Analyst Report?
Sinopharm Group Co (1099) Ratios
Sinopharm Group Co Ratios
HK:1099's free cash flow for Q2 2026 was $-26.59B. For the 2026 fiscal year, HK:1099's free cash flow was decreased by $-586.99M and operating cash flow was $-26.00B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.41 | 1.39 | 1.39 | 1.36 | 1.33 |
| Quick Ratio | 1.15 | 1.14 | 1.15 | 1.10 | 1.09 |
| Cash Ratio | 0.25 | 0.22 | 0.26 | 0.24 | 0.20 |
| Solvency Ratio | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
| Operating Cash Flow Ratio | 0.06 | 0.05 | 0.07 | 0.09 | 0.04 |
| Short-Term Operating Cash Flow Coverage | 0.22 | 0.18 | 0.31 | 0.40 | 0.17 |
| Net Current Asset Value | $ 90.63B | $ 81.30B | $ 73.76B | $ 64.70B | $ 55.16B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.28 | 0.19 | 0.19 | 0.19 | 0.20 |
| Debt-to-Equity Ratio | 1.29 | 0.97 | 0.99 | 1.02 | 1.10 |
| Debt-to-Capital Ratio | 0.56 | 0.49 | 0.50 | 0.51 | 0.52 |
| Long-Term Debt-to-Capital Ratio | 0.04 | 0.10 | 0.16 | 0.15 | 0.12 |
| Financial Leverage Ratio | 4.65 | 4.98 | 5.14 | 5.36 | 5.42 |
| Debt Service Coverage Ratio | 0.27 | 0.25 | 0.39 | 0.39 | 0.35 |
| Interest Coverage Ratio | 6.97 | 5.92 | 6.84 | 5.85 | 5.25 |
| Debt to Market Cap | 1.23 | 1.14 | 1.20 | 1.18 | 1.48 |
| Interest Debt Per Share | 35.55 | 25.35 | 24.59 | 23.43 | 23.18 |
| Net Debt to EBITDA | 2.19 | 1.09 | 0.37 | 0.55 | 1.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 7.25% | 7.57% | 8.13% | 8.59% | 8.45% |
| EBIT Margin | 3.00% | 3.05% | 3.77% | 4.00% | 3.98% |
| EBITDA Margin | 3.74% | 3.45% | 4.51% | 4.75% | 4.74% |
| Operating Profit Margin | 2.79% | 2.77% | 3.39% | 3.73% | 3.78% |
| Pretax Profit Margin | 2.57% | 2.40% | 3.27% | 3.36% | 3.26% |
| Net Profit Margin | 1.24% | 1.21% | 1.52% | 1.54% | 1.49% |
| Continuous Operations Profit Margin | 1.88% | 1.78% | 2.52% | 2.60% | 2.51% |
| Net Income Per EBT | 48.35% | 50.35% | 46.40% | 45.93% | 45.63% |
| EBT Per EBIT | 92.28% | 86.49% | 96.55% | 90.10% | 86.26% |
| Return on Assets (ROA) | 1.83% | 1.79% | 2.36% | 2.34% | 2.31% |
| Return on Equity (ROE) | 8.52% | 8.94% | 12.14% | 12.53% | 12.54% |
| Return on Capital Employed (ROCE) | 11.16% | 11.36% | 14.24% | 15.87% | 16.98% |
| Return on Invested Capital (ROIC) | 5.63% | 5.82% | 7.83% | 8.63% | 8.76% |
| Return on Tangible Assets | 1.88% | 1.85% | 2.42% | 2.42% | 2.40% |
| Earnings Yield | 13.13% | 11.29% | 15.85% | 15.59% | 18.06% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.78 | 2.83 | 3.21 | 3.23 | 3.02 |
| Payables Turnover | 4.73 | 3.44 | 3.54 | 3.49 | 3.59 |
| Inventory Turnover | 8.42 | 8.66 | 9.13 | 8.28 | 9.26 |
| Fixed Asset Turnover | 31.54 | 29.77 | 29.98 | 31.03 | 29.61 |
| Asset Turnover | 1.47 | 1.49 | 1.56 | 1.51 | 1.55 |
| Working Capital Turnover Ratio | 5.83 | 6.08 | 6.64 | 7.08 | 7.71 |
| Cash Conversion Cycle | 97.46 | 65.23 | 50.59 | 52.65 | 58.63 |
| Days of Sales Outstanding | 131.20 | 129.09 | 113.67 | 113.18 | 120.89 |
| Days of Inventory Outstanding | 43.35 | 42.13 | 39.98 | 44.06 | 39.41 |
| Days of Payables Outstanding | 77.09 | 105.98 | 103.06 | 104.58 | 101.67 |
| Operating Cycle | 174.55 | 171.21 | 153.65 | 157.24 | 160.30 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 4.53 | 3.70 | 5.50 | 6.72 | 2.99 |
| Free Cash Flow Per Share | 4.01 | 3.07 | 4.75 | 5.94 | 2.27 |
| Dividend Paid and CapEx Coverage Ratio | 3.78 | 2.47 | 3.51 | 4.41 | 2.11 |
| Capital Expenditure Coverage Ratio | 8.74 | 5.87 | 7.35 | 8.67 | 4.13 |
| Operating Cash Flow Coverage Ratio | 0.13 | 0.15 | 0.23 | 0.30 | 0.14 |
| Operating Cash Flow to Sales Ratio | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 |
| Free Cash Flow Yield | 22.98% | 15.34% | 25.98% | 33.92% | 16.41% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 7.62 | 8.86 | 6.31 | 6.41 | 5.54 |
| Price-to-Sales (P/S) Ratio | 0.09 | 0.11 | 0.10 | 0.10 | 0.08 |
| Price-to-Book (P/B) Ratio | 0.65 | 0.79 | 0.77 | 0.80 | 0.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.35 | 6.52 | 3.85 | 2.95 | 6.09 |
| Price-to-Operating Cash Flow Ratio | 3.85 | 5.41 | 3.33 | 2.61 | 4.62 |
| Price-to-Earnings Growth (PEG) Ratio | 5.74 | -0.40 | 1.01 | 0.67 | 0.71 |
| Enterprise Value Multiple | 4.72 | 4.19 | 2.49 | 2.63 | 2.75 |
| Enterprise Value | 101.53B | 84.50B | 67.09B | 69.04B | 67.81B |
| EV to EBITDA | 4.72 | 4.19 | 2.49 | 2.63 | 2.75 |
| EV to Sales | 0.18 | 0.14 | 0.11 | 0.13 | 0.13 |
| EV to Free Cash Flow | 8.11 | 8.82 | 4.52 | 3.72 | 9.62 |
| EV to Operating Cash Flow | 7.18 | 7.32 | 3.91 | 3.29 | 7.29 |
| Tangible Book Value Per Share | 39.76 | 37.73 | 35.35 | 31.42 | 28.11 |
| Shareholders’ Equity Per Share | 26.92 | 25.28 | 23.90 | 21.81 | 19.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.27 | 0.26 | 0.23 | 0.23 | 0.23 |
| Revenue Per Share | 184.32 | 187.31 | 191.17 | 176.93 | 167.48 |
| Net Income Per Share | 2.29 | 2.26 | 2.90 | 2.73 | 2.49 |
| Tax Burden | 0.48 | 0.50 | 0.46 | 0.46 | 0.46 |
| Interest Burden | 0.86 | 0.79 | 0.87 | 0.84 | 0.82 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.04 | 0.04 | 0.01 | 0.01 | 0.01 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.96 | 0.82 | 0.88 | 1.13 | 0.55 |
Currency in CNY
